Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone424-248-6500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$26.20 million
Profitability
Miscellaneous
Employees318
OptionableOptionable
Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."
How were Puma Biotechnology's earnings last quarter?
Puma Biotechnology Inc (NASDAQ:PBYI) announced its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.97) by $0.60. The biopharmaceutical company earned $62.60 million during the quarter, compared to analyst estimates of $57.94 million. Puma Biotechnology had a negative net margin of 73.45% and a negative return on equity of 301.41%. Puma Biotechnology's revenue was up 926.2% on a year-over-year basis. During the same period last year, the firm posted ($1.36) EPS. View Puma Biotechnology's Earnings History.
When is Puma Biotechnology's next earnings date?
What price target have analysts set for PBYI?
12 brokers have issued twelve-month price targets for Puma Biotechnology's shares. Their forecasts range from $21.00 to $151.00. On average, they anticipate Puma Biotechnology's share price to reach $64.7273 in the next year. This suggests a possible upside of 154.1% from the stock's current price. View Analyst Price Targets for Puma Biotechnology.
What is the consensus analysts' recommendation for Puma Biotechnology?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 sell ratings, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Puma Biotechnology.
What are Wall Street analysts saying about Puma Biotechnology stock?
Here are some recent quotes from research analysts about Puma Biotechnology stock:
- 1. According to Zacks Investment Research, "Puma Biotech's only marketed drug, Nerlynx, was approved for early stage HER2-positive breast cancer. The drug has improved sales steadily since launch in July 2017. Nerlynx was also approved in the EU during September, which can generate additional sales in the future quarters. However, sale of the drug in the third quarter of 2018 fell below expectations due to higher patient discontinuation. Meanwhile, several additional studies on Nerlynx targeting different types of breast cancer patient populations and in earlier-line settings are currently underway. The drug’s label expansion will allow it to treat and access an expanded patient population. Shares have underperformed the industry in 2018. Due to the lack of a strong pipeline, the company is totally dependent on Nerlynx for growth. Hence, any kind of regulatory setback for Nerlynx could affect the company’s growth prospects." (1/3/2019)
- 2. Cantor Fitzgerald analysts commented, ": We are lowering our 12-month price target to $50 from $75, but are maintaining our Overweight rating on shares of PBYI. Puma reported Nerlynx sales of $53M, which was under FactSet consensus of $58M. We are not necessarily lowering the price target due to the miss, but rather the explanations behind what are driving Nerlynx trends. We have slowed the ramp, increased discontinuations, and our 2025 Nerlynx revenues are $760M vs. $1.02B. We find the communication patterns related to the Nerlynx launch as highly challenging and tough to interpret. We increased the discount rate from 10% to 11% to proxy our view that we have lower visibility into these launch trends." (11/2/2018)
Has Puma Biotechnology been receiving favorable news coverage?
Media stories about PBYI stock have trended very positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Puma Biotechnology earned a media sentiment score of 3.7 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Puma Biotechnology's key competitors?
Some companies that are related to Puma Biotechnology include Array Biopharma (ARRY), Taro Pharmaceutical Industries (TARO), Intercept Pharmaceuticals (ICPT), Emergent Biosolutions (EBS), Agios Pharmaceuticals (AGIO), Evotec (EVTCY), Ascendis Pharma A/S (ASND), HUTCHISON CHINA/S (HCM), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT) and Amicus Therapeutics (FOLD).
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the folowing people:
- Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 48)
- Dr. Richard P. Bryce, Chief Medical & Scientific Officer (Age 61)
- Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 70)
- Mr. Steven Lo, Chief Commercial Officer (Age 51)
- Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 49)
Who are Puma Biotechnology's major shareholders?
Puma Biotechnology's stock is owned by many different of institutional and retail investors. Top institutional investors include Fox Run Management L.L.C. (0.05%) and Virtu Financial LLC (0.04%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.
Which major investors are buying Puma Biotechnology stock?
How do I buy shares of Puma Biotechnology?
Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Puma Biotechnology's stock price today?
One share of PBYI stock can currently be purchased for approximately $25.47.
How big of a company is Puma Biotechnology?
Puma Biotechnology has a market capitalization of $923.25 million and generates $26.20 million in revenue each year. The biopharmaceutical company earns $-291,950,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. Puma Biotechnology employs 318 workers across the globe.
What is Puma Biotechnology's official website?
How can I contact Puma Biotechnology?
Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]
MarketBeat Community Rating for Puma Biotechnology (NASDAQ PBYI)
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days.
